Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GDUFA Plus One: Stakeholders, FDA Confident As Review Goals Near

Executive Summary

Review metrics go into effect in another year, but times continue to increase; FDA and others still believe they are well on their way to meeting the generic drug user fee goals.

You may also be interested in...

PDUFA Communications Hurt By Sequestration As Late-Stage Meetings Begin

Twenty sponsors now have applications in the new review model, but none have reached the approval decision stage; industry officials say it still is too early to draw conclusions.

ANDA Sponsors May Need Extra Three Months To Avoid DMF-Related Delays

Under GDUFA, drug master files must pass a completeness assessment before they can be referenced in an ANDA. Sponsors should coordinate better with DMF holders to assure that FDA has adequate review time.

Generic User Fee Agreement Includes FDA Pledge To Determine Best Use Of Foreign Regulator Inspections

Draft commitment letter could be first step down globalization road in which FDA relies more on foreign governments to boost manufacturing oversight.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts